Ashley Ghiaseddin, MD : Research

In this study we are evaluating the safety and feasibility of the triple combination (TTFields, MLA, pembrolizumab) in adult patients diagnosed with recurrent or progressive glioblastoma (GBM) WHO Grade IV, IDH wild type or recurrent or progressive…

Investigator

Ashley Ghiaseddin

Status

Accepting Candidates

Ages

18 Years - 90 Years

Sexes

All

This is a multicenter, two-arm, randomized, double-blind, placebo-controlled study of Optune® (Tumor Treating Fields at 200 kHz) together with maintenance Temozolomide (TMZ) chemotherapy agent and pembrolizumab compared to Optune® together with…

Investigator

Ashley Ghiaseddin

Status

Accepting Candidates

Ages

18 Years - N/A

Sexes

All

This is a Phase I study to demonstrate the manufacturing feasibility and safety, and to determine the maximum tolerated dose (MTD) of RNA-LP vaccines in adult patients with recurrent glioblastoma.

Investigator

Ashley Ghiaseddin

Status

Accepting Candidates

Ages

18 Years - 80 Years

Sexes

All